Blueprint Medicines' IPO

Blueprint Medicines raised a round of funding on April 30, 2015. Investors include Public.

Blueprint Medicines is a patient-driven oncology company discovering and developing highly selective kinase inhibitors for genomically defined cancers. Led by a management team and advisors with world…

Articles about Blueprint Medicines' IPO: